KLRK1 and Miyoshi myopathy: NK cells from MM patients show a reduction in activating receptors NKG2D (aka killer cell lectin-like receptor K1/KLRK1), DNAX accessory molecule (DNAM)-1, and CD161, and an increase in inhibitory CD158a (inhibitory Killer Ig-like Receptor/KIR).